[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 5 of about 5
1. Seimiya YM, Takahashi M, Furukawa T, Mizutani K, Kimura K, Haritani M: An aged bull with concurrent thyroid C cell carcinoma, adrenal pheochromocytoma and pituitary chromophobe adenoma. J Vet Med Sci; 2009 Feb;71(2):225-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An aged bull with concurrent thyroid C cell carcinoma, adrenal pheochromocytoma and pituitary chromophobe adenoma.
  • Pathological examination disclosed multiple endocrine tumors including thyroid C cell carcinoma with metastases to the cervical lymph nodes and lung, adrenal pheochromocytoma and pituitary chromophobe adenoma in the pars distalis.


2. Minami I, Tateno T, Yoshimoto T, Doi M, Izumiyama H, Akashi T, Hirata Y: Subclinical Cushings disease with amelioration of metabolic comorbidities after removal of pituitary tumor. Intern Med; 2006;45(21):1231-5
MedlinePlus Health Information. consumer health - Weight Loss Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subclinical Cushings disease with amelioration of metabolic comorbidities after removal of pituitary tumor.
  • A 49-year-old woman with hypertension, obesity and impaired glucose tolerance (IGT) was admitted for evaluation of pituitary incidentaloma.
  • Although she presented no Cushingoid feature, endocrine examination of hypothalamo-pituitary-adrenal (HPA) axis showed elevated basal plasma ACTH and cortisol levels, their lack of circadian rhythm, non-suppressibility to low-dose (1 mg) dexamethasone, and responsiveness to CRH, suggesting autonomous ACTH secretion from a pituitary tumor.
  • She underwent transsphenoidal surgery, and was diagnosed as chromophobe adenoma with positive ACTH immunoreactivity.
  • Thus, her metabolic comorbidities are likely due to subclinical Cushings disease.
  • [MeSH-major] Glucose Intolerance / surgery. Hypertension / surgery. Obesity / surgery. Pituitary ACTH Hypersecretion / surgery. Pituitary Neoplasms / surgery
  • [MeSH-minor] Female. Humans. Middle Aged. Pituitary-Adrenal System / metabolism. Pituitary-Adrenal System / surgery

  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • MedlinePlus Health Information. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17139124.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


3. Brown RL, Muzzafar T, Wollman R, Weiss RE: A pituitary carcinoma secreting TSH and prolactin: a non-secreting adenoma gone awry. Eur J Endocrinol; 2006 May;154(5):639-43
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pituitary carcinoma secreting TSH and prolactin: a non-secreting adenoma gone awry.
  • To our knowledge, only one case of a TSH-secreting carcinoma has previously been reported.
  • We describe here a second patient with a pituitary carcinoma producing TSH and prolactin (PRL).
  • Pathologic examination revealed a chromophobe adenoma with increased mitotic forms.
  • The patient completed a course of external beam radiation to the pituitary and was prescribed l-thyroxine, bromocriptine, and hydrocortisone.
  • Emergent resection of the larger mass revealed a pituitary cancer with positive staining for PRL, but not for TSH.
  • Nine months later, the patient underwent further debulking of metastatic disease.
  • Although development of a carcinoma from a pituitary adenoma is very rare (<0.5%), macroadenomas that become hormonally active should be suspect for transformation into pituitary cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16645009.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK07011; United States / NCRR NIH HHS / RR / RR00055; United States / NCRR NIH HHS / RR / RR18372
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 9002-62-4 / Prolactin; 9002-71-5 / Thyrotropin
  •  go-up   go-down


Advertisement
4. Chung TT, Evanson J, Walker D, Akker SA, Besser GM, Monson JP, Grossman AB, Drake WM: Safety of GH replacement in hypopituitary patients with nonirradiated pituitary and peripituitary tumours. Clin Endocrinol (Oxf); 2008 Jun;68(6):965-9
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety of GH replacement in hypopituitary patients with nonirradiated pituitary and peripituitary tumours.
  • BACKGROUND: Published data suggest that growth hormone replacement (GHR) may be given safely to patients with hypopituitarism consequent upon a pituitary/peripituitary tumour.
  • However, a preponderance of patients treated with external pituitary irradiation were included.
  • OBJECTIVE: To assess the safety of GHR in nonirradiated pituitary/peripituitary tumour.
  • PATIENTS: We imaged prospectively the pituitary glands of 48 patients (18 males; mean age 51.6 years range 21-77) who had adult onset growth hormone deficiency (AO-GHD) after appropriate treatment for a pituitary/peripituitary tumour but who did not receive external pituitary irradiation.
  • Pituitary surveillance imaging was performed prior to the commencement of GHR, at 6-12 months and then yearly.
  • Three patients were judged to have an apparent increase in tumour volume and/or marker, although only one was thought to be possibly GH related--a patient with a cystic chromophobe adenoma who demonstrated a marginal increase in residual tumour volume 4 years after commencement of GHR.
  • CONCLUSION: These data add to the growing body of evidence for the safety of GHR in hypopituitary patients consequent upon pituitary/peripituitary mass lesions and represents the first reported series in a heterogeneous group of nonirradiated patients.
  • [MeSH-major] Human Growth Hormone / adverse effects. Human Growth Hormone / therapeutic use. Hypopituitarism / drug therapy. Pituitary Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18031317.001).
  • [ISSN] 1365-2265
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone
  •  go-up   go-down






Advertisement